Literature DB >> 20516447

Serious ethical dilemma of single-agent pegylated liposomal Doxorubicin employed as a control arm in ovarian cancer chemotherapy trials.

Maurie Markman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20516447     DOI： 10.1200/JCO.2010.28.9934

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

Authors:  Theresa A Lawrie; Andrew Bryant; Alison Cameron; Emma Gray; Jo Morrison
Journal:  Cochrane Database Syst Rev       Date:  2013-07-09

2.  Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.

Authors:  Takashi Motohashi; Akira Yabuno; Hiroshi Michimae; Tetsuro Ohishi; Miwa Nonaka; Masashi Takano; Shin Nishio; Hiroyuki Fujiwara; Keiichi Fujiwara; Eiji Kondo; Toru Sugiyama; Tsutomu Tabata
Journal:  J Gynecol Oncol       Date:  2020-11-10       Impact factor: 4.401

3.  2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy.

Authors:  Revathi Ananthakrishnan; Stephanie Green; Daniel Li; Michael LaValley
Journal:  Contemp Clin Trials Commun       Date:  2019-10-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.